Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:46673rdf:typepubmed:Citationlld:pubmed
pubmed-article:46673lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:46673lifeskim:mentionsumls-concept:C0025202lld:lifeskim
pubmed-article:46673lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:46673lifeskim:mentionsumls-concept:C0002520lld:lifeskim
pubmed-article:46673lifeskim:mentionsumls-concept:C0010665lld:lifeskim
pubmed-article:46673lifeskim:mentionsumls-concept:C0232813lld:lifeskim
pubmed-article:46673lifeskim:mentionsumls-concept:C0699829lld:lifeskim
pubmed-article:46673pubmed:issue1lld:pubmed
pubmed-article:46673pubmed:dateCreated1975-5-17lld:pubmed
pubmed-article:46673pubmed:abstractText5-S-cysteinyldopa has been demonstrated in the plasma of two patients with metastases of malignant melanoma and a high excretion rate of 5-S-cysteinyldopa in the urine. In one patient the plasma clearance of 5-S-cysteinyl dopa was 30 ml/min and in the other 69 ml/min. These clearance values were 43 and 45%, respectively, of the creatinine clearance in the two patients.lld:pubmed
pubmed-article:46673pubmed:languageenglld:pubmed
pubmed-article:46673pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:46673pubmed:citationSubsetIMlld:pubmed
pubmed-article:46673pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:46673pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:46673pubmed:statusMEDLINElld:pubmed
pubmed-article:46673pubmed:issn0001-5555lld:pubmed
pubmed-article:46673pubmed:authorpubmed-author:FalckBBlld:pubmed
pubmed-article:46673pubmed:authorpubmed-author:RosengrenEElld:pubmed
pubmed-article:46673pubmed:authorpubmed-author:RorsmanHHlld:pubmed
pubmed-article:46673pubmed:authorpubmed-author:RosengrenA...lld:pubmed
pubmed-article:46673pubmed:authorpubmed-author:AgrupGGlld:pubmed
pubmed-article:46673pubmed:authorpubmed-author:AnderssonTTlld:pubmed
pubmed-article:46673pubmed:authorpubmed-author:PerssonKKlld:pubmed
pubmed-article:46673pubmed:issnTypePrintlld:pubmed
pubmed-article:46673pubmed:volume55lld:pubmed
pubmed-article:46673pubmed:ownerNLMlld:pubmed
pubmed-article:46673pubmed:authorsCompleteYlld:pubmed
pubmed-article:46673pubmed:pagination5-6lld:pubmed
pubmed-article:46673pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:46673pubmed:meshHeadingpubmed-meshheading:46673-Hu...lld:pubmed
pubmed-article:46673pubmed:meshHeadingpubmed-meshheading:46673-Br...lld:pubmed
pubmed-article:46673pubmed:meshHeadingpubmed-meshheading:46673-Sk...lld:pubmed
pubmed-article:46673pubmed:meshHeadingpubmed-meshheading:46673-Li...lld:pubmed
pubmed-article:46673pubmed:meshHeadingpubmed-meshheading:46673-Cy...lld:pubmed
pubmed-article:46673pubmed:meshHeadingpubmed-meshheading:46673-Lu...lld:pubmed
pubmed-article:46673pubmed:meshHeadingpubmed-meshheading:46673-Ma...lld:pubmed
pubmed-article:46673pubmed:meshHeadingpubmed-meshheading:46673-Me...lld:pubmed
pubmed-article:46673pubmed:meshHeadingpubmed-meshheading:46673-Ad...lld:pubmed
pubmed-article:46673pubmed:meshHeadingpubmed-meshheading:46673-Di...lld:pubmed
pubmed-article:46673pubmed:meshHeadingpubmed-meshheading:46673-Ne...lld:pubmed
pubmed-article:46673pubmed:year1975lld:pubmed
pubmed-article:46673pubmed:articleTitle5-S-cysteinyldopa in the plasma of melanoma patients and the renal clearance of this amino acid.lld:pubmed
pubmed-article:46673pubmed:publicationTypeJournal Articlelld:pubmed